Index RUT
P/E -
EPS (ttm) -0.51
Insider Own 6.05%
Shs Outstand 43.12M
Perf Week -2.42%
Market Cap 296.42M
Forward P/E 39.58
EPS next Y 0.17
Insider Trans -4.76%
Shs Float 40.59M
Perf Month -10.56%
Income -21.72M
PEG -
EPS next Q -0.07
Inst Own 74.78%
Short Float 4.26%
Perf Quarter -24.12%
Sales 159.01M
P/S 1.86
EPS this Y 6.86%
Inst Trans 4.21%
Short Ratio 4.35
Perf Half Y 64.51%
Book/sh 2.22
P/B 3.09
EPS next Y 209.47%
ROA -11.07%
Short Interest 1.73M
Perf Year -32.21%
Cash/sh 0.86
P/C 8.00
EPS next 5Y -
ROE -22.08%
52W Range 3.45 - 10.83
Perf YTD 0.44%
Dividend Est. -
P/FCF -
EPS past 5Y 3.44%
ROI -13.29%
52W High -36.67%
Beta 1.06
Dividend TTM -
Quick Ratio 2.14
Sales past 5Y 13.87%
Gross Margin 80.42%
52W Low 98.84%
ATR (14) 0.36
Dividend Ex-Date Jan 27, 2010
Current Ratio 2.89
EPS Y/Y TTM 26.43%
Oper. Margin -13.50%
RSI (14) 35.21
Volatility 4.98% 4.24%
Employees 428
Debt/Eq 0.72
Sales Y/Y TTM 14.74%
Profit Margin -13.66%
Recom 1.00
Target Price 13.67
Option/Short Yes / Yes
LT Debt/Eq 0.71
EPS Q/Q 29.38%
Payout -
Rel Volume 1.03
Prev Close 6.50
Sales Surprise 4.00%
EPS Surprise 16.08%
Sales Q/Q 18.69%
Earnings May 02 BMO
Avg Volume 397.41K
Price 6.86
SMA20 -8.26%
SMA50 -20.53%
SMA200 -3.84%
Trades
Volume 408,395
Change 5.54%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-11-22 Resumed
Jefferies
Buy
$15
May-09-22 Upgrade
Canaccord Genuity
Hold → Buy
$10 → $15
Mar-11-22 Resumed
Cantor Fitzgerald
Overweight
$21
Oct-23-20 Initiated
Guggenheim
Buy
$24
Jun-16-20 Resumed
Cantor Fitzgerald
Overweight
$16
May-07-20 Downgrade
Canaccord Genuity
Buy → Hold
$12
Apr-02-20 Downgrade
BTIG Research
Buy → Neutral
Aug-07-19 Downgrade
William Blair
Outperform → Mkt Perform
Jul-12-19 Initiated
Canaccord Genuity
Buy
$32
Mar-02-18 Reiterated
Lake Street
Buy
$26 → $38
Jan-05-18 Resumed
Cantor Fitzgerald
Overweight
Nov-30-17 Initiated
Jefferies
Buy
$35
Nov-21-17 Reiterated
Lake Street
Buy
$22 → $26
Jul-31-17 Initiated
Leerink Partners
Outperform
$22
Jun-30-17 Initiated
Cantor Fitzgerald
Overweight
$18
Mar-06-17 Initiated
ROTH Capital
Buy
$14.50
Nov-22-16 Upgrade
Lake Street
Hold → Buy
$9 → $11
Nov-07-16 Reiterated
Wedbush
Outperform
$10 → $12
Nov-03-16 Downgrade
Lake Street
Buy → Hold
$9
Aug-04-16 Reiterated
Wedbush
Outperform
$9 → $10
Show Previous Ratings
Apr-16-24 07:00AM
Mar-08-24 11:55PM
Mar-06-24 08:20AM
Mar-05-24 09:27PM
(Thomson Reuters StreetEvents) -15.11%
11:53AM
07:38AM
Loading…
07:38AM
(Associated Press Finance)
07:31AM
07:00AM
Feb-28-24 08:50AM
Feb-26-24 09:15AM
Feb-13-24 04:30PM
Feb-12-24 08:50AM
Feb-06-24 09:40AM
Feb-02-24 04:15PM
Jan-26-24 08:50AM
05:00PM
Loading…
Jan-18-24 05:00PM
Jan-04-24 04:45PM
04:40PM
04:35PM
Dec-26-23 04:15PM
Dec-06-23 07:00AM
Dec-01-23 05:00PM
Nov-20-23 07:00AM
Nov-08-23 09:41AM
Nov-07-23 11:01PM
(Thomson Reuters StreetEvents) +36.90%
08:04AM
07:15AM
(Associated Press Finance)
07:00AM
Nov-02-23 10:00AM
Oct-31-23 10:01AM
07:00AM
Loading…
Oct-18-23 07:00AM
Oct-16-23 10:23AM
Sep-28-23 08:21AM
Sep-05-23 07:00AM
Aug-31-23 07:00AM
Aug-21-23 07:00AM
Aug-10-23 03:03PM
12:05PM
Aug-08-23 10:59AM
(Simply Wall St.) -19.44%
05:57AM
(Thomson Reuters StreetEvents)
Aug-07-23 05:25PM
04:18PM
04:01PM
Aug-03-23 05:55PM
Jul-27-23 07:00AM
Jul-26-23 07:00AM
Jun-10-23 10:42AM
Jun-09-23 09:55AM
May-24-23 07:00AM
May-12-23 07:00AM
May-09-23 08:35AM
07:34AM
07:00AM
Apr-18-23 04:05PM
07:25AM
Mar-17-23 04:31AM
Mar-16-23 06:30AM
Mar-14-23 11:23PM
(Thomson Reuters StreetEvents) +11.95%
07:00AM
Mar-06-23 07:00AM
Mar-02-23 04:00PM
Mar-01-23 09:21AM
Feb-13-23 07:00AM
Jan-09-23 07:00AM
Jan-05-23 07:00AM
Jan-04-23 07:00AM
Jan-01-23 08:52AM
Dec-19-22 07:00AM
Nov-11-22 08:50AM
Nov-08-22 08:15AM
08:00AM
(Thomson Reuters StreetEvents)
07:00AM
Nov-03-22 04:00PM
Oct-31-22 07:00AM
Oct-27-22 12:00PM
Oct-20-22 07:00AM
Oct-19-22 09:40AM
Sep-29-22 05:32AM
Sep-22-22 09:55AM
07:00AM
Aug-08-22 09:55AM
09:40AM
Aug-03-22 05:25PM
04:01PM
Jul-29-22 07:00AM
Jul-25-22 08:24AM
Jul-20-22 03:26PM
Jul-18-22 04:00PM
Jul-11-22 07:00AM
May-25-22 07:12AM
May-18-22 07:00AM
May-05-22 10:58AM
May-04-22 07:45PM
04:05PM
04:01PM
Apr-15-22 09:33AM
Apr-13-22 07:00AM
Mar-17-22 07:00AM
Feb-22-22 06:15PM
04:34PM
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Scopelianos Angelo Chief R&D Officer Mar 21 '24 Option Exercise 0.00 2,500 0 58,604 Mar 25 09:37 PM Zaderej Karen L. CEO Mar 21 '24 Sale 7.68 39,280 301,670 1,124,565 Mar 25 09:43 PM Scopelianos Angelo Chief R&D Officer Mar 21 '24 Sale 7.68 6,881 52,846 52,999 Mar 25 09:37 PM Donovan Michael Patrick VP Operations Mar 21 '24 Sale 7.68 6,033 46,333 37,992 Mar 25 09:22 PM DeVinney Erick Wayne Chief Innovation Officer Mar 21 '24 Sale 7.68 4,578 35,159 165,661 Mar 25 09:40 PM Zaderej Karen L. CEO Mar 16 '24 Option Exercise 0.00 110,322 0 1,157,593 Mar 25 09:43 PM DeVinney Erick Wayne Chief Innovation Officer Mar 16 '24 Option Exercise 0.00 18,675 0 180,615 Mar 25 09:40 PM Scopelianos Angelo Chief R&D Officer Mar 16 '24 Option Exercise 0.00 25,406 0 58,250 Mar 25 09:37 PM Donovan Michael Patrick VP Operations Mar 16 '24 Option Exercise 0.00 24,575 0 58,846 Mar 25 09:22 PM Donovan Michael Patrick VP Operations Mar 07 '24 Sale 8.81 36,310 319,891 35,708 Mar 08 05:33 PM Freitag Gregory Gene Director Mar 07 '24 Sale 9.00 25,000 225,000 271,594 Mar 08 05:31 PM MARIANI PETER J EVP & Chief Financial Officer Dec 11 '23 Sale 7.50 12,500 93,809 63,603 Dec 13 04:07 PM Wendell Amy McBride Director Sep 06 '23 Buy 6.22 10,000 62,240 80,342 Sep 08 04:20 PM Burke William P. Mr. Director Aug 23 '23 Buy 6.56 10,000 65,600 10,000 Aug 25 04:16 PM NEELS GUIDO J Director Aug 16 '23 Buy 6.11 10,000 61,100 68,259 Aug 18 04:12 PM Freitag Gregory Gene Director Jun 01 '23 Option Exercise 0.00 6,459 0 296,594 Jun 05 06:47 PM NEELS GUIDO J Director Jun 01 '23 Option Exercise 0.00 6,459 0 58,259 Jun 05 06:52 PM JOHNSON JOHN Director Jun 01 '23 Option Exercise 0.00 6,459 0 6,459 Jun 05 06:53 PM Levine Alan M Director Jun 01 '23 Option Exercise 0.00 6,459 0 18,259 Jun 05 06:57 PM THOMAS PAUL Director Jun 01 '23 Option Exercise 0.00 6,459 0 9,495 Jun 05 06:22 PM Wendell Amy McBride Director Jun 01 '23 Option Exercise 0.00 6,459 0 70,342 Jun 05 06:24 PM Freitag Gregory Gene Director Jun 01 '23 Sale 8.71 41,980 365,780 290,135 Jun 05 06:47 PM Freitag Gregory Gene Director May 23 '23 Sale 9.23 7,468 68,899 332,115 May 24 04:12 PM Wendell Amy McBride Director May 12 '23 Option Exercise 9.22 28,750 265,075 63,883 May 16 04:31 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite